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Introduction:myelosuppression is primary toxicity of many chemotherapy regimens
and limits their applicability. Use of G-CSF is important to reduce incidence of febrile
neutropenia, but is burdened with bone pain.
Objectives: evaluate safety and toxicity of a single injection of pegfilgrastim compared
to daily administration of lenograstim in breast cancer patient undergoing adjuvant
chemotherapy.
Methods: single injection of Pegfilgrastim compared to 5 daily administrations of
Lenograstim in a population of 56 women undergoing chemotherapy with FEC-100 for
6 cycles (Group A) or 3 FEC-100 followed by 3 DOCETAXEL-100 (Group B).
Results: In Group A, 40% of patients showed Neutropenia-G4, 35,3% of those treated
with Lenograstim, while 44,4% of those treated with Pegfilgrastim. in Goup B, 57,1% of
patients showed Neutropenia-G4: 75,0% of those treated with Lenograstim and 33,3%
of patients treated with Pegfilgrastim (p = 0,005). Overall, 30,4% of all patients
developed BP with intensity of 7-10 second Numeric Rating Scale. Bone Pain incidence
was significantly higher in Group B than in Group A (52,4% vs 17,1%, p = 0,005), with
no significant differences between Lenograstim and Pegfilgrastim. In both groups, the
average duration of Bone Pain was 4-6 days.
Conclusions: Both G-CSFs showed efficacy in reduction of Neutropenia, but
Pegfilgrastim showed a better action with similar side effects in Group B. Moreover,
Pegfilgrastim could be a better choice for patient’s compliance because of single
injection in front of 5 necessary for L. Overall, Bone Pain incidence was significantly
higher in Group B than in Group A (p = 0,005), with no significant differences between
Lenograstim and Pegfilgrastim.
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